It was very much as expected, but the following comments are most interesting:
* no adverse events (most important for approval to sell)
* accelerated review of 45 days for approval(makes first quarter look safe)
* still anticipating commercial partner deal this month (this must mean all the due diligence and financing is complete, and agreement has been reached, leaving only formal completion)
I am very happy with the outlook, and see the remaining hurdles as relatively low risk.
The current selling of TIS I think must be a big buyer wanting to scare holders into selling. I won't be.
- Forums
- ASX - By Stock
- TIS
- eu final clinical trial results released..
eu final clinical trial results released.., page-5
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)